» Articles » PMID: 35453310

Hyperthermia Treatment As a Promising Anti-Cancer Strategy: Therapeutic Targets, Perspective Mechanisms and Synergistic Combinations in Experimental Approaches

Overview
Date 2022 Apr 23
PMID 35453310
Authors
Affiliations
Soon will be listed here.
Abstract

Despite recent developments in diagnosis and treatment options, cancer remains one of the most critical threats to health. Several anti-cancer therapies have been identified, but further research is needed to provide more treatment options that are safe and effective for cancer. Hyperthermia (HT) is a promising treatment strategy for cancer because of its safety and cost-effectiveness. This review summarizes studies on the anti-cancer effects of HT and the detailed mechanisms. In addition, combination therapies with anti-cancer drugs or natural products that can effectively overcome the limitations of HT are reviewed because HT may trigger protective events, such as an increase of heat shock proteins (HSPs). In the 115 reports included, the mechanisms related to apoptosis, cell cycle, reactive oxygen species, mitochondrial membrane potential, DNA damage, transcription factors and HSPs were considered important. This review shows that HT is an effective inducer of apoptosis. Moreover, the limitations of HT may be overcome using combined therapy with anti-cancer drugs or natural products. Therefore, appropriate combinations of such agents with HT will exert maximal effects to treat cancer.

Citing Articles

Synergistic effects of 6-shogaol and hyperthermia on ACHN renal cancer cells: modulation of ROS and heat shock pro-teins in cancer therapy.

Ahn C, Baek S Front Pharmacol. 2025; 16:1522285.

PMID: 40051570 PMC: 11882530. DOI: 10.3389/fphar.2025.1522285.


Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.

Benjamin A, Nayak S Discov Nano. 2025; 20(1):18.

PMID: 39883285 PMC: 11782756. DOI: 10.1186/s11671-024-04163-w.


Targeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.

Kennedy B, Noftall E, Dean C, Roth A, Clark K, Rowles D Front Immunol. 2025; 15:1512543.

PMID: 39872527 PMC: 11769938. DOI: 10.3389/fimmu.2024.1512543.


Recent advancements and clinical aspects of engineered iron oxide nanoplatforms for magnetic hyperthermia-induced cancer therapy.

Rajan A, Laha S, Sahu N, Thorat N, Shankar B Mater Today Bio. 2024; 29:101348.

PMID: 39669801 PMC: 11636219. DOI: 10.1016/j.mtbio.2024.101348.


Investigation of the Application of Reduced Graphene Oxide-SPION Quantum Dots for Magnetic Hyperthermia.

Omar H, Alkurdi Y, Fathima A, Alsharaeh E Nanomaterials (Basel). 2024; 14(19).

PMID: 39404274 PMC: 11477580. DOI: 10.3390/nano14191547.


References
1.
Kaveh S, Ebrahimi P, Rezapour A, Mozafari M, Sayehmiri K . Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment: systematic review and meta-analysis. Int J Clin Pharm. 2019; 41(1):30-41. DOI: 10.1007/s11096-018-0754-1. View

2.
DIncalci M . Trabectedin mechanism of action: what's new?. Future Oncol. 2013; 9(12 Suppl):5-10. DOI: 10.2217/fon.13.207. View

3.
DeNardo S, DeNardo G, Miers L, Natarajan A, Foreman A, Gruettner C . Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res. 2005; 11(19 Pt 2):7087s-7092s. DOI: 10.1158/1078-0432.CCR-1004-0022. View

4.
Lushnikova E, Ovsyanko E, Nepomnyashchikh L, Efremov A, Morozov D . Proliferation of Walker 256 carcinosarcoma cells: effect of whole-body hyperthermia and antitumor agents. Bull Exp Biol Med. 2012; 152(1):146-52. DOI: 10.1007/s10517-011-1475-9. View

5.
Wachsberger P, Burd R, Wahl M, Leeper D . Betulinic acid sensitization of low pH adapted human melanoma cells to hyperthermia. Int J Hyperthermia. 2002; 18(2):153-64. DOI: 10.1080/02656730110091333. View